We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 2,241

Personalized medicine: patent issues in Canada and Europe

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, European Union
  • -
  • October 16 2014

Canada Introduction 'Personalized medicine', in its broadest aspects, is essentially the tailoring of treatments to individual characteristics, needs

Appealing medical device patent cases

  • Knobbe Martens Olson & Bear LLP
  • -
  • USA
  • -
  • October 15 2014

Medical device patent infringement cases, like all patent infringement cases, must be appealed to the U.S. Court of Appeals for the Federal Circuit

Supreme Court hears oral argument in Teva Pharmaceuticals v. Sandoz

  • Fitzpatrick, Cella, Harper & Scinto
  • -
  • USA
  • -
  • October 15 2014

On October 15, 2014, the Supreme Court of the United States heard oral argument in Teva Pharmaceuticals USA, Inc., et al. V. Sandoz, Inc., et al., No

Costa Rican Patent Office position as to Swiss type claims

  • CastroPal Abogados
  • -
  • Costa Rica
  • -
  • October 14 2014

According to the Costa Rican Patent Law, methods of treatment or diagnosis are considered non- patentable subject matter in Costa Rica, as well as

Canadian Competition Bureau provides preliminary guidance on pharma patent settlements

  • McCarthy Tétrault LLP
  • -
  • Canada
  • -
  • October 14 2014

Settlements of patent litigation between brand name and generic pharmaceutical companies have been the subject of significant antitrustcompetition

Determining infringement by reference to ANDA specification and the physical product likely to be sold

  • Cohen & Gresser LLP
  • -
  • USA
  • -
  • October 10 2014

In Hatch-Waxman litigation, the filing of an ANDA seeking approval to market a pharmaceutical product before the expiration of patents covering that

Proposals to extend R&D protection against patent infringement for companies in the pharmaceutical sector

  • Mason Hayes & Curran
  • -
  • Ireland
  • -
  • October 10 2014

On 31 July 2014, the Irish legislature published the Intellectual Property (Miscellaneous Provisions) Bill 2014. This Bill will, among other things

The Purple Book & the PTAB

  • Oblon Spivak LLP
  • -
  • USA
  • -
  • October 8 2014

In September, the FDA began publishing the "Purple Book." The Purple Book is the biologic counterpart to the long running Orange Book for "small

Dow prevails over Nova in polymer patent suit

  • Smart & Biggar/Fetherstonhaugh
  • -
  • Canada
  • -
  • October 8 2014

The Dow Chemical Company (“Dow”) has prevailed in a Canadian patent infringement suit against Nova Chemicals Corporation (“Nova”) relating to Nova’s

The BRCA1 case: a Myriad of possibilities

  • ENSafrica
  • -
  • Australia, USA
  • -
  • October 7 2014

In an interesting development, contrary to the finding of the US Supreme Court in a similar case in the United States, the Australian Federal Court